| 12.21 0.16 (1.33%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.19 | 1-year : | 17.74 |
| Resists | First : | 13.01 | Second : | 15.19 |
| Pivot price | 11.28 |
|||
| Supports | First : | 11.52 | Second : | 10.6 |
| MAs | MA(5) : | 11.8 |
MA(20) : | 11.28 |
| MA(100) : | 12.82  |
MA(250) : | 14.47 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 90.7 |
D(3) : | 83.8 |
| RSI | RSI(14): 57.7 |
|||
| 52-week | High : | 25.45 | Low : | 10.6 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IART ] has closed Bollinger Bands are 37.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.38 - 12.42 | 12.42 - 12.46 |
| Low: | 11.69 - 11.73 | 11.73 - 11.78 |
| Close: | 12.13 - 12.2 | 12.2 - 12.27 |
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Thu, 19 Feb 2026
Integra LifeSciences (IART) to Release Earnings on Thursday - MarketBeat
Tue, 17 Feb 2026
Integra LifeSciences appoints new CTO and key executives - Investing.com
Tue, 17 Feb 2026
Integra LifeSciences Announces Key Executive Leadership Appointments - GlobeNewswire
Tue, 10 Feb 2026
Allianz Asset Management GmbH Boosts Stock Position in Integra LifeSciences Holdings Corporation $IART - MarketBeat
Mon, 09 Feb 2026
Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 78 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 13.9 (%) |
| Held by Institutions | 96.5 (%) |
| Shares Short | 7,430 (K) |
| Shares Short P.Month | 6,880 (K) |
| EPS | -6.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.32 |
| Profit Margin | -30.2 % |
| Operating Margin | 9.9 % |
| Return on Assets (ttm) | 2.5 % |
| Return on Equity (ttm) | -38.8 % |
| Qtrly Rev. Growth | 5.5 % |
| Gross Profit (p.s.) | 12.12 |
| Sales Per Share | 21.05 |
| EBITDA (p.s.) | 4.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 89 (M) |
| Levered Free Cash Flow | 90 (M) |
| PE Ratio | -1.88 |
| PEG Ratio | 0 |
| Price to Book value | 0.91 |
| Price to Sales | 0.57 |
| Price to Cash Flow | 10.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|